Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elicio Therapeutics (ELTX) Short-term Investments (2022 - 2025)

Elicio Therapeutics filings provide 2 years of Short-term Investments readings, the most recent being $722000.0 for Q4 2023.

  • On a quarterly basis, Short-term Investments fell 56.0% to $722000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $722000.0, a 56.0% decrease, with the full-year FY2023 number at $722000.0, down 56.0% from a year prior.
  • Short-term Investments hit $722000.0 in Q4 2023 for Elicio Therapeutics, down from $1.7 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $1.7 million in Q3 2023 to a low of $722000.0 in Q4 2023.